146 related articles for article (PubMed ID: 34203549)
1. ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response.
Ehlers FAI; Beelen NA; van Gelder M; Evers TMJ; Smidt ML; Kooreman LFS; Bos GMJ; Wieten L
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34203549
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
3. NKG2A Expression Is Not
Mahaweni NM; Ehlers FAI; Sarkar S; Janssen JWH; Tilanus MGJ; Bos GMJ; Wieten L
Front Immunol; 2018; 9():1415. PubMed ID: 29988376
[TBL] [Abstract][Full Text] [Related]
4. Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages.
Ehlers FAI; Mahaweni NM; van de Waterweg Berends A; Saya T; Bos GMJ; Wieten L
Cancer Immunol Immunother; 2023 Jun; 72(6):1789-1801. PubMed ID: 36656341
[TBL] [Abstract][Full Text] [Related]
5. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
7. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
9. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
10. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
Terszowski G; Klein C; Stern M
J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
[TBL] [Abstract][Full Text] [Related]
11. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling.
Stein MN; Shin J; Gudzowaty O; Bernstein AM; Liu JM
Anticancer Res; 2006; 26(3A):1759-63. PubMed ID: 16827104
[TBL] [Abstract][Full Text] [Related]
13. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.
van Gelder M; Vanclée A; van Elssen CH; Hupperets P; Wieten L; Bos GM
Breast Cancer Res Treat; 2017 Feb; 161(3):421-433. PubMed ID: 27915436
[TBL] [Abstract][Full Text] [Related]
15. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
16. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
Sarkar S; van Gelder M; Noort W; Xu Y; Rouschop KM; Groen R; Schouten HC; Tilanus MG; Germeraad WT; Martens AC; Bos GM; Wieten L
Cancer Immunol Immunother; 2015 Aug; 64(8):951-63. PubMed ID: 25920521
[TBL] [Abstract][Full Text] [Related]
17. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
Ewen EM; Pahl JHW; Miller M; Watzl C; Cerwenka A
Eur J Immunol; 2018 Feb; 48(2):355-365. PubMed ID: 29105756
[TBL] [Abstract][Full Text] [Related]
18. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.
Gooneratne SL; Center RJ; Kent SJ; Parsons MS
Clin Exp Immunol; 2016 Apr; 184(1):101-9. PubMed ID: 26647083
[TBL] [Abstract][Full Text] [Related]
19. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
20. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
